About: Characterization of trans- and cis-cleavage activity of the SARS coronavirus 3CL(pro) protease: basis for the in vitro screening of anti-SARS drugs

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Characterization of trans- and cis-cleavage activity of the SARS coronavirus 3CL(pro) protease: basis for the in vitro screening of anti-SARS drugs Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Characterization of trans- and cis-cleavage activity of the SARS coronavirus 3CL(pro) protease: basis for the in vitro screening of anti-SARS drugs
Creator	Lin, Cheng-Wen Wan, Lei Chen, Pei-Jer Lin, Kuan-Hsun Lai, Chien-Chen »more»
source	Elsevier; Medline; PMC
abstract	Severe acute respiratory syndrome (SARS) has been globally reported. A novel coronavirus (CoV), SARS-CoV, was identified as the etiological agent of the disease. SARS-CoV 3C-like protease (3CL(pro)) mediates the proteolytic processing of replicase polypeptides 1a and 1ab into functional proteins, playing an important role in viral replication. In this study, we demonstrated the expression of the SARS-CoV 3CL(pro) in Escherichia coli and Vero cells, and then characterized the in vitro trans-cleavage and the cell-based cis-cleavage by the 3CL(pro). Mutational analysis of the 3CL(pro) demonstrated the importance of His41, Cys145, and Glu166 in the substrate-binding subsite S1 for keeping the proteolytic activity. In addition, alanine substitution of the cleavage substrates indicated that Gln-(P1) in the substrates mainly determined the cleavage efficiency. Therefore, this study not only established the quantifiable and reliable assay for the in vitro and cell-based measurement of the 3CL(pro) activity, but also characterized the molecular interaction of the SARS-CoV 3CL(pro) with the substrates. The results will be useful for the rational development of the anti-SARS drugs.
has issue date	2004-09-10(xsd:dateTime)
bibo:doi	10.1016/j.febslet.2004.08.017
bibo:pmid	15358553
has license	no-cc
sha1sum (hex)	dcad16a8b7cb1dac87ed9f2144d4a498ee4dfca2
schema:url	https://doi.org/10.1016/j.febslet.2004.08.017
resource representing a document's title	Characterization of trans- and cis-cleavage activity of the SARS coronavirus 3CL(pro) protease: basis for the in vitro screening of anti-SARS drugs
has PubMed Central identifier	PMC7127318
has PubMed identifier	15358553
schema:publication	FEBS Lett
resource representing a document's body	covid:dcad16a8b7cb1dac87ed9f2144d4a498ee4dfca2#body_text
is schema:about of	named entity 'demonstrated' named entity 'globally' named entity 'drugs' named entity 'SARS-CoV' named entity 'substrates' »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software